niacin trial summary

Cardiovascular prevention

All chronical situations: 11 trials - CLAS - CLAS - Carlson (Stockholm) - CDP niacin - VA drugs - AIM-HIGH - HPS 2-Thrive - Oxford Niaspan Study - ARBITER 2 - HATS - ARBITER 6-HALTS (niacin vs ezetimibe)

clofibtate+niacin vs placebo

No demonstrated result

suggested Coronary death by 36% (not demonstrated)

Endpoint	TE [95% CI]	p val	I2	n	k	trials
Venous thromboembolism	no data
cardiovascular events	no data
Cardiovascular death	no data
stroke (fatal and non fatal)	no data
Coronary event	0.71 [0.50 1.02]	p=1.00	0	555	1	Carlson (Stockholm),
Coronary death and non fatal MI	no data
Coronary death	0.64 [0.42 0.96]	p=0.04	0	555	1	Carlson (Stockholm),
cardiac death	no data
MACE	no data
Non fatal MI	0.69 [0.43 1.11]	p=1.00	0	555	1	Carlson (Stockholm),
All cause death	0.74 [0.50 1.08]	p=1.00	0	555	1	Carlson (Stockholm),
non cardiovascular death	no data
Fatal stroke	no data
Haemmorhagic stroke	no data
new-onset diabetes	no data
Death from cancer	0.66 [0.18 2.36]	p=1.00	0	555	1	Carlson (Stockholm),
Rhabdomyolysis	no data
Myopathy	no data
Cancer	no data
Adverse events	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

colestipol-niacin vs placebo

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
Amputation	no data
Venous thromboembolism	no data
cardiovascular events	no data
Cardiovascular death	no data
stroke (fatal and non fatal)	no data
Coronary event	no data
Coronary death and non fatal MI	no data
Coronary death	no data
cardiac death	no data
MACE	no data
Non fatal MI	no data
Revascularization	no data
All cause death	0.33 [0.01 8.29]	p=1.00	0	188	1	CLAS,
non cardiovascular death	no data
Fatal stroke	no data
Haemmorhagic stroke	no data
new-onset diabetes	no data
Death from cancer	no data
Rhabdomyolysis	no data
Myopathy	no data
Cancer	no data
Adverse events	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

niacin vs control

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
Venous thromboembolism	no data
cardiovascular events	no data
Cardiovascular death	no data
stroke (fatal and non fatal)	no data
Coronary event	no data
Coronary death and non fatal MI	no data
Coronary death	no data
cardiac death	1.05 [0.50 2.21]	p=1.00	0	220	1	VA drugs,
MACE	no data
Non fatal MI	no data
All cause death	1.03 [0.51 2.08]	p=1.00	0	220	1	VA drugs,
non cardiovascular death	0.93 [0.17 5.19]	p=1.00	0	220	1	VA drugs,
Fatal stroke	no data
Haemmorhagic stroke	no data
new-onset diabetes	no data
Death from cancer	no data
Rhabdomyolysis	no data
Myopathy	no data
Cancer	no data
Adverse events	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

niacin vs ezetimibe

No demonstrated result

suggested cardiovascular events by 2849% (not demonstrated)

suggested Coronary event by 79% (not demonstrated)

Endpoint	TE [95% CI]	p val	I2	n	k	trials
cardiovascular events	29.49 [15.39 56.51]	p=0.04	0	363	1	ARBITER 6-HALTS (niacin vs ezetimibe),
Cardiovascular death	no data
stroke (fatal and non fatal)	no data
Coronary event	0.21 [0.04 0.98]	p=0.04	0	363	1	ARBITER 6-HALTS (niacin vs ezetimibe),
All cause death	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

niacin vs placebo

No demonstrated result

suggested Coronary event by 15% (not demonstrated)

suggested Non fatal MI by 26% (not demonstrated)

Endpoint	TE [95% CI]	p val	I2	n	k	trials
Venous thromboembolism	no data
cardiovascular events	no data
Cardiovascular death	no data
stroke (fatal and non fatal)	no data
Coronary event	0.85 [0.73 1.00]	p=0.04	0	3908	1	CDP niacin,
Coronary death and non fatal MI	no data
Coronary death	0.95 [0.79 1.13]	p=1.00	0	3908	1	CDP niacin,
cardiac death	no data
MACE	no data
Non fatal MI	0.74 [0.59 0.92]	p=0.04	0	3908	1	CDP niacin,
All cause death	0.96 [0.82 1.13]	p=1.00	0	3908	1	CDP niacin,
non cardiovascular death	1.15 [0.76 1.72]	p=1.00	0	3908	1	CDP niacin,
Fatal stroke	no data
Haemmorhagic stroke	no data
new-onset diabetes	no data
Death from cancer	0.93 [0.43 2.02]	p=1.00	0	3908	1	CDP niacin,
Rhabdomyolysis	no data
Myopathy	no data
Cancer	no data
Adverse events	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

niacin vs placebo (on top statin)

No demonstrated result

Endpoint	TE [95% CI]	p val	n	k	trials
cardiovascular events	0.96 [0.90 1.03]	p=1.00	29414	4	AIM-HIGH,HPS 2-Thrive,ARBITER 2,HATS,
Cardiovascular death	1.09 [0.95 1.24]	p=1.00	26000	3	HPS 2-Thrive,ARBITER 2,HATS,
stroke (fatal and non fatal)	1.02 [0.90 1.15]	p=1.00	29330	4	AIM-HIGH,HPS 2-Thrive,ARBITER 2,HATS,
Coronary event	0.97 [0.88 1.07]	p=1.00	29325	4	AIM-HIGH,HPS 2-Thrive,ARBITER 2,HATS,
All cause death	1.09 [0.98 1.21]	p=1.00	25833	2	HPS 2-Thrive,HATS,

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

See more clinical conditions

All type of patients: 13 trials - CLAS - Carlson (Stockholm) - CDP niacin - VA drugs - AIM-HIGH - HPS 2-Thrive - Oxford Niaspan Study - ARBITER 2 - HATS - ARBITER 6-HALTS (niacin vs ezetimibe) - Guyton - UCSF SCOR - FATS

clofibtate+niacin vs placebo

No demonstrated result

suggested Coronary death by 36% (not demonstrated)

Endpoint	TE [95% CI]	p val	I2	n	k	trials
Venous thromboembolism	no data
cardiovascular events	no data
Cardiovascular death	no data
stroke (fatal and non fatal)	no data
Coronary event	0.71 [0.50 1.02]	p=1.00	0	555	1	Carlson (Stockholm),
Coronary death and non fatal MI	no data
Coronary death	0.64 [0.42 0.96]	p=0.04	0	555	1	Carlson (Stockholm),
cardiac death	no data
MACE	no data
Non fatal MI	0.69 [0.43 1.11]	p=1.00	0	555	1	Carlson (Stockholm),
All cause death	0.74 [0.50 1.08]	p=1.00	0	555	1	Carlson (Stockholm),
non cardiovascular death	no data
Fatal stroke	no data
Haemmorhagic stroke	no data
new-onset diabetes	no data
Death from cancer	0.66 [0.18 2.36]	p=1.00	0	555	1	Carlson (Stockholm),
Rhabdomyolysis	no data
Myopathy	no data
Cancer	no data
Adverse events	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

colestipol-niacin vs placebo

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
Venous thromboembolism	no data
cardiovascular events	no data
Cardiovascular death	no data
stroke (fatal and non fatal)	no data
Coronary event	no data
Coronary death and non fatal MI	no data
Coronary death	no data
cardiac death	no data
MACE	no data
Non fatal MI	no data
All cause death	no data
non cardiovascular death	no data
Fatal stroke	no data
Haemmorhagic stroke	no data
new-onset diabetes	no data
Death from cancer	no data
Rhabdomyolysis	no data
Myopathy	no data
Cancer	no data
Adverse events	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

niacin vs control

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
Venous thromboembolism	no data
cardiovascular events	no data
Cardiovascular death	no data
stroke (fatal and non fatal)	no data
Coronary event	no data
Coronary death and non fatal MI	no data
Coronary death	no data
cardiac death	1.05 [0.50 2.21]	p=1.00	0	220	1	VA drugs,
MACE	no data
Non fatal MI	no data
All cause death	1.03 [0.51 2.08]	p=1.00	0	220	1	VA drugs,
non cardiovascular death	0.93 [0.17 5.19]	p=1.00	0	220	1	VA drugs,
Fatal stroke	no data
Haemmorhagic stroke	no data
new-onset diabetes	no data
Death from cancer	no data
Rhabdomyolysis	no data
Myopathy	no data
Cancer	no data
Adverse events	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

niacin vs ezetimibe

No demonstrated result

suggested cardiovascular events by 2849% (not demonstrated)

suggested Coronary event by 79% (not demonstrated)

Endpoint	TE [95% CI]	p val	I2	n	k	trials
cardiovascular events	29.49 [15.39 56.51]	p=0.04	0	363	1	ARBITER 6-HALTS (niacin vs ezetimibe),
Cardiovascular death	no data
stroke (fatal and non fatal)	no data
Coronary event	0.21 [0.04 0.98]	p=0.04	0	363	1	ARBITER 6-HALTS (niacin vs ezetimibe),
All cause death	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

niacin vs placebo

No demonstrated result

suggested Coronary event by 15% (not demonstrated)

suggested Non fatal MI by 26% (not demonstrated)

Endpoint	TE [95% CI]	p val	I2	n	k	trials
Venous thromboembolism	no data
cardiovascular events	no data
Cardiovascular death	no data
stroke (fatal and non fatal)	no data
Coronary event	0.85 [0.73 1.00]	p=0.04	0	3908	1	CDP niacin,
Coronary death and non fatal MI	no data
Coronary death	0.95 [0.79 1.13]	p=1.00	0	3908	1	CDP niacin,
cardiac death	no data
MACE	no data
Non fatal MI	0.74 [0.59 0.92]	p=0.04	0	3908	1	CDP niacin,
All cause death	0.96 [0.82 1.13]	p=1.00	0	3908	1	CDP niacin,
non cardiovascular death	1.15 [0.76 1.72]	p=1.00	0	3908	1	CDP niacin,
Fatal stroke	no data
Haemmorhagic stroke	no data
new-onset diabetes	no data
Death from cancer	0.93 [0.43 2.02]	p=1.00	0	3908	1	CDP niacin,
Rhabdomyolysis	no data
Myopathy	no data
Cancer	no data
Adverse events	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

niacin vs placebo (on top statin)

No demonstrated result

Endpoint	TE [95% CI]	p val	n	k	trials
cardiovascular events	0.96 [0.90 1.03]	p=1.00	29414	4	AIM-HIGH,HPS 2-Thrive,ARBITER 2,HATS,
Cardiovascular death	1.09 [0.95 1.24]	p=1.00	26000	3	HPS 2-Thrive,ARBITER 2,HATS,
stroke (fatal and non fatal)	1.02 [0.90 1.15]	p=1.00	29330	4	AIM-HIGH,HPS 2-Thrive,ARBITER 2,HATS,
Coronary event	0.97 [0.88 1.07]	p=1.00	29325	4	AIM-HIGH,HPS 2-Thrive,ARBITER 2,HATS,
All cause death	1.09 [0.98 1.21]	p=1.00	25833	2	HPS 2-Thrive,HATS,

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

niacin+colestipol vs control

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
cardiovascular events	0.34 [0.01 8.57]	p=1.00	0	97	1	UCSF SCOR,
Cardiovascular death	no data
stroke (fatal and non fatal)	no data
Coronary event	0.34 [0.01 8.57]	p=1.00	0	97	1	UCSF SCOR,
All cause death	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

niacin+colestipol vs placebo

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
cardiovascular events	0.22 [0.04 1.05]	p=1.00	0	100	1	FATS,
Cardiovascular death	no data
stroke (fatal and non fatal)	no data
Coronary event	no data
All cause death	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

niacin+ezetimibe vs simvastatin+ezetimibe

No demonstrated result

suggested cardiovascular events by 2153% (not demonstrated)

Endpoint	TE [95% CI]	p val	I2	n	k	trials
cardiovascular events	22.53 [5.52 91.90]	p=0.04	0	948	1	Guyton,
Cardiovascular death	no data
stroke (fatal and non fatal)	0.13 [0.01 3.30]	p=1.00	0	948	1	Guyton,
Coronary event	0.40 [0.03 6.46]	p=1.00	0	948	1	Guyton,
All cause death	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Patients with prior MI or with CHD: 3 trials - CLAS - CDP niacin - VA drugs

colestipol-niacin vs placebo

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
Venous thromboembolism	no data
cardiovascular events	no data
Cardiovascular death	no data
stroke (fatal and non fatal)	no data
Coronary event	no data
Coronary death and non fatal MI	no data
Coronary death	no data
cardiac death	no data
MACE	no data
Non fatal MI	no data
All cause death	no data
non cardiovascular death	no data
Fatal stroke	no data
Haemmorhagic stroke	no data
new-onset diabetes	no data
Death from cancer	no data
Rhabdomyolysis	no data
Myopathy	no data
Cancer	no data
Adverse events	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

niacin vs control

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
Venous thromboembolism	no data
cardiovascular events	no data
Cardiovascular death	no data
stroke (fatal and non fatal)	no data
Coronary event	no data
Coronary death and non fatal MI	no data
Coronary death	no data
cardiac death	1.05 [0.50 2.21]	p=1.00	0	220	1	VA drugs,
MACE	no data
Non fatal MI	no data
All cause death	1.03 [0.51 2.08]	p=1.00	0	220	1	VA drugs,
non cardiovascular death	0.93 [0.17 5.19]	p=1.00	0	220	1	VA drugs,
Fatal stroke	no data
Haemmorhagic stroke	no data
new-onset diabetes	no data
Death from cancer	no data
Rhabdomyolysis	no data
Myopathy	no data
Cancer	no data
Adverse events	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

niacin vs placebo

No demonstrated result

suggested Coronary event by 15% (not demonstrated)

suggested Non fatal MI by 26% (not demonstrated)

Endpoint	TE [95% CI]	p val	I2	n	k	trials
Venous thromboembolism	no data
cardiovascular events	no data
Cardiovascular death	no data
stroke (fatal and non fatal)	no data
Coronary event	0.85 [0.73 1.00]	p=0.04	0	3908	1	CDP niacin,
Coronary death and non fatal MI	no data
Coronary death	0.95 [0.79 1.13]	p=1.00	0	3908	1	CDP niacin,
cardiac death	no data
MACE	no data
Non fatal MI	0.74 [0.59 0.92]	p=0.04	0	3908	1	CDP niacin,
All cause death	0.96 [0.82 1.13]	p=1.00	0	3908	1	CDP niacin,
non cardiovascular death	1.15 [0.76 1.72]	p=1.00	0	3908	1	CDP niacin,
Fatal stroke	no data
Haemmorhagic stroke	no data
new-onset diabetes	no data
Death from cancer	0.93 [0.43 2.02]	p=1.00	0	3908	1	CDP niacin,
Rhabdomyolysis	no data
Myopathy	no data
Cancer	no data
Adverse events	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Peripheral vascular diseases

All type of patients: 1 trials - CLAS

colestipol-niacin vs placebo

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
Amputation	no data
Cardiovascular death	no data
Revascularization	no data
All cause death	0.33 [0.01 8.29]	p=1.00	0	188	1	CLAS,

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Post myocardial infarction

All type of patients: 1 trials - Carlson (Stockholm)

clofibtate+niacin vs placebo

No demonstrated result

suggested Coronary death by 36% (not demonstrated)

Endpoint	TE [95% CI]	p val	I2	n	k	trials
Venous thromboembolism	no data
cardiovascular events	no data
Cardiovascular death	no data
stroke (fatal and non fatal)	no data
Coronary event	0.71 [0.50 1.02]	p=1.00	0	555	1	Carlson (Stockholm),
Coronary death and non fatal MI	no data
Coronary death	0.64 [0.42 0.96]	p=0.04	0	555	1	Carlson (Stockholm),
cardiac death	no data
MACE	no data
Non fatal MI	0.69 [0.43 1.11]	p=1.00	0	555	1	Carlson (Stockholm),
All cause death	0.74 [0.50 1.08]	p=1.00	0	555	1	Carlson (Stockholm),
non cardiovascular death	no data
Fatal stroke	no data
Haemmorhagic stroke	no data
new-onset diabetes	no data
Death from cancer	0.66 [0.18 2.36]	p=1.00	0	555	1	Carlson (Stockholm),
Rhabdomyolysis	no data
Myopathy	no data
Cancer	no data
Adverse events	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Niacin cholesterol lowering intervention

Lithium Nicotinate - Enduracin - Wampocap - Nicotinate - Nicolar - Nicocap - Nicobid - Nico400 - Nico 400 - Nico-400 - Nicamin - Induracin - 3 Pyridinecarboxylic Acid - 3-Pyridinecarboxylic Acid - Nicotinic Acid - Niacin

Cardiovascular prevention

Peripheral vascular diseases

Post myocardial infarction